Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients.

Schindler E, Amantea MA, Karlsson MO, Friberg LE.

CPT Pharmacometrics Syst Pharmacol. 2017 Jun;6(6):373-382. doi: 10.1002/psp4.12193. Epub 2017 May 26.

2.

Lack of effect of smoking status on axitinib pharmacokinetics in patients with non-small-cell lung cancer.

Garrett M, Taylor T, Mould DR, Amantea MA, Chen Y, Ingrosso A, Pithavala YK.

Cancer Chemother Pharmacol. 2016 Dec;78(6):1131-1141. doi: 10.1007/s00280-016-3164-x. Epub 2016 Oct 25.

PMID:
27783139
3.

Clinical Trial Simulations From a Model-Based Meta-Analysis of Studies in Patients With Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy.

Zierhut ML, Chen Y, Pithavala YK, Nickens DJ, Valota O, Amantea MA.

CPT Pharmacometrics Syst Pharmacol. 2016 May;5(5):274-82. doi: 10.1002/psp4.12078. Epub 2016 May 15.

4.

PK-PD modeling of individual lesion FDG-PET response to predict overall survival in patients with sunitinib-treated gastrointestinal stromal tumor.

Schindler E, Amantea MA, Karlsson MO, Friberg LE.

CPT Pharmacometrics Syst Pharmacol. 2016 Apr;5(4):173-81. doi: 10.1002/psp4.12057. Epub 2016 Mar 16.

5.

PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST.

Hansson EK, Ma G, Amantea MA, French J, Milligan PA, Friberg LE, Karlsson MO.

CPT Pharmacometrics Syst Pharmacol. 2013 Dec 4;2:e85. doi: 10.1038/psp.2013.62.

6.

PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST.

Hansson EK, Amantea MA, Westwood P, Milligan PA, Houk BE, French J, Karlsson MO, Friberg LE.

CPT Pharmacometrics Syst Pharmacol. 2013 Nov 20;2:e84. doi: 10.1038/psp.2013.61.

7.

Population pharmacokinetic analysis of axitinib in healthy volunteers.

Garrett M, Poland B, Brennan M, Hee B, Pithavala YK, Amantea MA.

Br J Clin Pharmacol. 2014 Mar;77(3):480-92. doi: 10.1111/bcp.12206.

8.

Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies.

Sarapa N, Nickens DJ, Raber SR, Reynolds RR, Amantea MA.

Clin Pharmacol Ther. 2008 Jan;83(1):153-9. Epub 2007 Jun 20.

PMID:
17581594
9.

Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies.

Vail DM, Amantea MA, Colbern GT, Martin FJ, Hilger RA, Working PK.

Semin Oncol. 2004 Dec;31(6 Suppl 13):16-35. Review.

PMID:
15717736
10.
11.

The population pharmacokinetics of amphotericin B colloidal dispersion in patients receiving bone marrow transplants.

Amantea MA, Bowden RA, Forrest A, Working PK, Newman MS, Mamelok RD.

Chemotherapy. 1999 Jun;45 Suppl 1:48-53.

PMID:
10394021
12.

Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice.

Newman MS, Colbern GT, Working PK, Engbers C, Amantea MA.

Cancer Chemother Pharmacol. 1999;43(1):1-7. Erratum in: Cancer Chemother Pharmacol 1999;43(6):524.

PMID:
9923534
13.

Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis.

Forrest A, Chodosh S, Amantea MA, Collins DA, Schentag JJ.

J Antimicrob Chemother. 1997 Dec;40 Suppl A:45-57.

PMID:
9484873
14.

Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma.

Amantea MA, Forrest A, Northfelt DW, Mamelok R.

Clin Pharmacol Ther. 1997 Mar;61(3):301-11.

PMID:
9084455
15.

Modified oral ondansetron regimen for cyclophosphamide-induced emesis in lupus nephritis.

Yarboro CH, Wesley R, Amantea MA, Klippel JH, Pucino F.

Ann Pharmacother. 1996 Jul-Aug;30(7-8):752-5.

PMID:
8826554
16.

Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma.

Northfelt DW, Martin FJ, Working P, Volberding PA, Russell J, Newman M, Amantea MA, Kaplan LD.

J Clin Pharmacol. 1996 Jan;36(1):55-63.

PMID:
8932544
17.

Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants.

Amantea MA, Bowden RA, Forrest A, Working PK, Newman MS, Mamelok RD.

Antimicrob Agents Chemother. 1995 Sep;39(9):2042-7.

18.

Pharmacokinetics and safety of weekly dapsone and dapsone plus pyrimethamine for prevention of pneumocystis pneumonia.

Falloon J, Lavelle J, Ogata-Arakaki D, Byrne A, Graziani A, Morgan A, Amantea MA, Ownby K, Polis M, Davey RT Jr, et al.

Antimicrob Agents Chemother. 1994 Jul;38(7):1580-7.

19.

Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits.

Lee JW, Amantea MA, Francis PA, Navarro EE, Bacher J, Pizzo PA, Walsh TJ.

Antimicrob Agents Chemother. 1994 Apr;38(4):713-8.

20.

Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.

Roberts JW, Cora-Locatelli G, Bravi D, Amantea MA, Mouradian MM, Chase TN.

Neurology. 1993 Dec;43(12):2685-8.

PMID:
8255478
21.

Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers.

Kan VL, Bennett JE, Amantea MA, Smolskis MC, McManus E, Grasela DM, Sherman JW.

J Infect Dis. 1991 Aug;164(2):418-21.

PMID:
1856491
22.

Pharmacokinetics of oral and intravenous omeprazole in patients with the Zollinger-Ellison syndrome.

Vinayek R, Amantea MA, Maton PN, Frucht H, Gardner JD, Jensen RT.

Gastroenterology. 1991 Jul;101(1):138-47.

PMID:
2044903
23.

Role of CD4 in HIV infection and therapy.

Amantea MA.

Am J Hosp Pharm. 1991 Jun;48(6):1300. No abstract available.

PMID:
1677530
24.

Standardization of a fluconazole bioassay and correlation of results with those obtained by high-pressure liquid chromatography.

Rex JH, Hanson LH, Amantea MA, Stevens DA, Bennett JE.

Antimicrob Agents Chemother. 1991 May;35(5):846-50.

25.

Should the dosage of zidovudine be adjusted in HIV-infected patients with impaired renal function?

Amantea MA.

Am J Hosp Pharm. 1990 Mar;47(3):618-9. No abstract available.

PMID:
2316548
26.

Visual compatibility of zidovudine with other injectable drugs during simulated Y-site administration.

Bashaw ED, Amantea MA, Minor JR, Gallelli JF.

Am J Hosp Pharm. 1988 Dec;45(12):2532-3. No abstract available.

PMID:
3228107
27.

Improved procedure for quantitation of omeprazole and metabolites using reversed-phase high-performance liquid chromatography.

Amantea MA, Narang PK.

J Chromatogr. 1988 Apr 8;426(1):216-22. No abstract available.

PMID:
3384874

Supplemental Content

Loading ...
Support Center